Breast Cancer
MDR1 phosphorothioate antisense oligodeoxynucleotides abate resistant cancers
Published in Gene Therapy Weekly, September 18th, 2003
"The effect of MDR1 antisense phosphorothiate oligodeoxynucleotides (S-ODNs) on resistant phenotype was investigated in multidrug-resistant human colon carcinoma and breast carcinoma cells in vitro and in vivo. Drug resistance in human colon carcinoma (SW620 Ad300) and breast carcinoma (MCF-7/INT500, MCF-71AD150 and MCF-7/TH) cell lines is predominantly due to overexpression of P-glycoprotein (P-gp) resulting in decreased daunorubicin (DNR) accumulation," investigators in the United States report.
"Two MDR1] antisense S-ODNs, one complementary to the initial 15 bases of...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2003-09-18)
More Articles from Gene Therapy Weekly
- Breast Cancer
Estradiol enhances tumor regression in breast cancer models given gene therapy - Ovarian Cancer
Epithelial ovarian carcinomas overexpress high mobility group A 1 proteins - Gene Therapy
Systemic gene delivery lessens pathology in an orthotopic bladder cancer model - Melanoma
Melanoma cells normally tolerant to endogenous p53 respond to p53 transduction - Transduction
A new adaptor protein reactivates mutant p53 to cause tumor destruction - Brain Cancer
Downstream-regulated gene 2 inhibits glioblastoma cell growth - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
